Protagonist Therapeutics, Inc. announced that Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in first quarter of 2022. Topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis expected in second quarter of 2022. Dosing has begun in a 240-patient Phase 2b clinical trial of PN-235 in moderate-to-severe plaque psoriasis, sponsored by Janssen.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.76 USD | -3.66% | -1.31% | +8.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.55% | 1.5B | |
+0.89% | 43.84B | |
+5.55% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.10% | 25.53B | |
-24.78% | 18.18B | |
-3.10% | 12.29B | |
+25.98% | 12.29B | |
+6.77% | 11.15B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces Pivotal Phase 3 VERIFY Study of Rusfertide in Polycythemia Vera Expected to Initiate in First Quarter of 2022